File(s) not publicly available
Simvastatin treatment reduces heat shock protein 60, 65, and 70 antibody titers in dyslipidemic patients: A randomized, double-blind, placebo-controlled, cross-over trial
journal contribution
posted on 2023-06-08, 13:46 authored by Mohsen Moohebati, Shirin Bidmeshgi, Mahmoud R Azarpazhooh, Mahdi Hassanzadeh Daloee, Majid Ghayour-Mobarhan, Shima Tavallaie, Maral Amini, Akram Momenzadeh, Amirhossein Sahebkar, Roghayeh Paydar, Amir A Rahsepar, Seyyed M R Parizadeh, Saeed Akhlaghi, Gordon FernsGordon FernsOBJECTIVE This study aimed to evaluate the effects of statin therapy on serum levels of antibodies to several specific heat shock proteins (HSPs) in dyslipidemic patients. DESIGN AND METHODS Participants (n=102) were treated with simvastatin (40mg/day), or placebo in a randomized, double-blind, placebo-controlled, cross-over trial. Anti-HSP60, 65, 70, and hs-CRP levels were measured before and after each treatment period. Seventy-seven subjects completed the study. RESULTS Treatment with simvastatin was associated with significant reductions in serum anti-HSP60, 65, and 70 titers in the dyslipidemic patients (10%, 14%, and 15% decrease, respectively) (p<0.001). There have been previous reports of reductions in serum CRP with statin treatment, and although median CRP levels were 9% lower on simvastatin treatment, this did not achieve statistical significance. CONCLUSION While it is unclear whether HSP antibodies are directly involved in atherogenesis, our findings suggest that simvastatin inhibits autoimmune responses that may contribute to the development of cardiovascular disease
History
Publication status
- Published
Journal
Clinical BiochemistryISSN
0009-9120Publisher
ElsevierIssue
2-3Volume
44Page range
192-197Department affiliated with
- Division of Medical Education Publications
Full text available
- No
Peer reviewed?
- Yes
Legacy Posted Date
2012-11-19Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC